Recent news coverage includes broader market and sector developments but lacks company-specific updates for Jushi Holdings Inc.

• No recent company-specific news was identified in the primary business news sources for Jushi Holdings Inc. as of late 2026 [N1][N2][N3][N4][N5][N6][N7][N8].

Jushi benefits from its strategic corporate restructuring to Nevada, aligning its legal domicile with operational focus in the U.S. cannabis market. The partial federal rescheduling of medical cannabis products to Schedule III may reduce tax burdens and regulatory hurdles for its medical cannabis operations. Experienced leadership and a strong governance framework support operational execution. The company’s presence in states transitioning to adult-use markets, such as Virginia, offers potential for market expansion and revenue diversification. Continued compliance and adaptation to evolving regulations could enhance operational efficiency and market positioning.

Jushi faces significant risks from the ongoing federal illegality of cannabis, including potential criminal and civil penalties that could materially impact its business and financial condition. The complexity and uncertainty of federal regulatory changes, including the pending DEA administrative hearings and litigation, create operational and compliance challenges. The company’s financial results show sustained losses and liquidity constraints, with a current ratio below 1. Operational execution risks exist in managing market transitions, such as Virginia's adult-use legalization, amid increasing competition and cost pressures. Tax provisions under IRS Code Section 280E continue to affect profitability despite partial rescheduling relief.

Jushi operates in the highly regulated and federally complex U.S. cannabis industry, which creates significant barriers to entry due to licensing, compliance, and federal-state legal conflicts. The company's established presence in multiple states, experienced leadership, and governance structure contribute to operational stability. However, the lack of federal legalization and ongoing regulatory uncertainty limit the company's ability to fully leverage competitive advantages. The partial rescheduling of medical cannabis products may provide some tax and regulatory relief, but the overall regulatory environment remains a significant moat against new entrants and a challenge for existing operators.

• Federal Cannabis Illegality and Enforcement Risk: Cannabis remains illegal under U.S. federal law as a Schedule I controlled substance, exposing Jushi to potential criminal charges, fines, and administrative sanctions that could materially affect its business and financial condition [S2].
• Regulatory and Compliance Uncertainty: Ongoing DEA administrative hearings, litigation challenging rescheduling rules, and unclear impacts of partial rescheduling create uncertainty around regulatory compliance, tax treatment, and operational requirements [S2].
• Financial and Liquidity Risks: The company reported a net loss of $68.6 million for fiscal 2025 and has a current ratio of 0.79 as of September 30, 2026, indicating liquidity constraints that may affect operational flexibility [S1,S2].
• Operational Execution Risks: Transitioning to adult-use markets such as Virginia involves risks related to production capacity, inventory management, staffing, competition, and cost control that could limit the realization of anticipated benefits [S2].
• Tax Burden under IRS Code Section 280E: Despite partial relief from 280E for state-licensed medical cannabis operations registered with the DEA, differences in tax treatment between medical and non-medical cannabis products may increase accounting and compliance costs [S2].

• Jushi Holdings Inc. is a cannabis company domiciled in Nevada as of July 2026, having completed a Continuance from British Columbia, Canada to Nevada to better align corporate structure with operations [S2].
• The company derives 100% of its revenues from the cannabis industry [S2].
• Jushi operates in multiple U.S. states where medical and/or adult-use cannabis is authorized at the state level, but cannabis remains illegal under U.S. federal law as a Schedule I controlled substance [S2].
• The company is subject to significant regulatory risks due to federal illegality, including potential criminal charges, fines, and administrative sanctions [S2].
• The DEA has partially rescheduled FDA-approved cannabis products and state-licensed medical cannabis products to Schedule III as of April 28, 2026, which may provide some tax relief under IRS Code Section 280E for medical cannabis operations if registered with the DEA [S2].
• The company’s financial snapshot as of September 30, 2026, shows cash and equivalents of $28.7 million, current assets of $74.1 million, current liabilities of $93.6 million, a current ratio of 0.79, and a cash ratio of 0.31 [S2].
• The company reported a net loss of $68.6 million for fiscal year 2025 and basic and diluted EPS of -$0.06 for Q3 2026 [S1,S2].
• Jushi’s board consists of five directors, four of whom are independent under Canadian Securities Administrators Guidelines, with diverse backgrounds in finance, commodities, consumer brands, and management consulting [S1].
• The executive leadership includes CEO and Chairman James Cacioppo, President and Chief Revenue Officer Louis J. Barack, and CFO Michelle O. Mosier, all with extensive experience in finance and consumer industries [S1].
• The company faces operational risks related to the transition of Virginia to an adult-use cannabis market starting July 1, 2027, including execution of production capacity, inventory, staffing, and competition management [S2].
• The company’s governance includes three standing committees: Audit, Nominating and Corporate Governance, and Compensation, with detailed charters and oversight responsibilities [S1].
• Recent business news coverage does not specifically mention Jushi but includes broader market and sector developments [N1-N8].